Ensayos clínicos en América Latina: implicancias para la sustentabilidad y seguridad de los mercados farmacéuticos y el bienestar de los sujetos
Recibido:
24 julio 2016,
Aceptado:
22 septiembre 2016,
Publicado:
4 octubre 2016
Resumen
Este estudio buscó verificar si los medicamentos aprobados por la Food and Drug Administration (FDA) de EE.UU. fueron registrados, comercializados y vendidos a precios accesibles en los países latinoamericanos en los que fueron testeados, además de constatar su contribución a la calidad del mercado farmacéutico. Se consultó la lista de nuevas entidades moleculares (NEM) aprobadas por la FDA en 2011 y 2012 para identificar los países en los cuales se realizaron ensayos pivotales. Se analizó la accesibilidad económica como proporción de ingresos y se recolectó información sobre seguridad y eficacia en boletines independientes de medicamentos. En los dos años analizados, se testearon 33 medicamentos en 12 países latinoamericanos. Solo el 60% de los registros esperados se habían completado para septiembre de 2014. A excepción de uno, todos los productos para los cuales se obtuvo información de precio (n=18) costaron más que un sueldo mínimo mensual en todos los países. Solo cinco medicamentos fueron clasificados como “posiblemente mejores que otros tratamientos disponibles”. Solo una de las NEM satisface las prioridades de la atención médica de los países de bajos y medianos ingresos.
Referencias bibliográficas
1. Express Scripts. Drug trend report [Internet]. 2010 [citado 10 may 2015]. Disponible en: http://goo.gl/kOSQvQ
2. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrigton RA, Califf RM, Schulman K. Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine. 2009;360(8):816-823.
3. Wenner DM. The social value of knowledge and international clinical research. Developing World Bioethics. 2015;15(2):76-84.
4. Homedes N, Ugalde A. Globalization and clinical research in Latin America. In: Homedes N, Ugalde A, (eds). Clinical trials in Latin America: where ethics and business clash. Dordrecht: Springer; 2014. p 55-78.
5. Durivage HJ, Bridges KD. Clinical trial metrics: Protocol performance and resource utilization from 14 cancer centers. Journal of Clinical Oncology. 2009;27(Suppl 15):6557.
6. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research involving human subjects. Geneva: CIOMS; 2002.
7. Vargas-Pélaez CM, Mattozo Rover MR, Leite SN, Rossi Buenaventura F, Rocha Farias M. Right to health, essential medicines, and lawsuits for access to medicines - A scoping study. Social Science and Medicine 2014;121:48-55.
8. Homedes N, Ugalde A. Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Bulletin of the World Health Organization. 2015;93(10):674-683.
9. Homedes N, Ugalde A. Health and ethical consequences of outsourcing pivotal clinical trials to Latin America: A cross-sectional, descriptive study. PLoS One. 2016;11(6):e0157756.
10. Homedes N, Ugalde A. Are private interests clouding the peer-review process of the WHO Bulletin?: A case study. Accountability in Research. 2016;23(5):309-317.
11. Food and Drug Administration. 2011 novel drug [Internet]. FDA; 2012 [citado 10 may 2016]. Disponible en: http://goo.gl/dPZ0tI
12. Food and Drug Administration. Novel drug approvals for 2012 [Internet]. 2016 [citado 10 may 2016]. Disponible en: http://goo.gl/OCd2Fk
13. Drugs@FDA [Internet]. Silver Spring: Food and Drug Administration; 2015 [citado 15 may 2015]. Disponible en: http://goo.gl/aM8sbK.
14. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Vademecum Nacional de Medicamentos [Internet]. Buenos Aires: ANMAT; 2014 [citado 27 may 2015]. Disponible en: http://goo.gl/QIF6v4.
15. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. Listado oficial de medicamentos comercializados [Internet]. Buenos Aires: ANMAT; 2014. Disponible en: http://goo.gl/Gnrx0E.
16. Agência Nacional de Vigilância Sanitária. Listas de Preços de Medicamentos [Internet]. Brasília: ANVISA; 2015 [citado 15 may 2015]. Disponible en: http://tinyurl.com/nwe9go4.
17. Agência Nacional de Vigilância Sanitária. Medicamentos Analisados [Internet]. Brasília: ANVISA; 2015 [citado 10 may 2015]. Disponible en: http://goo.gl/M2tnEf.
18. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Consulta datos de productos [Internet]. Bogotá: INVIMA; 2014 [citado 15 may 2015]. Disponible en: http://goo.gl/VhICMI.
19. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Listado de entidades químicas con información no divulgada protegida según el Decreto 2085 de 2002 [Internet]. Bogotá: INVIMA; 2014 [citado 15 may 2015]. Disponible en: http://goo.gl/kY1vDu.
20. Ministerio de Salud y Protección Social. Precios de Medicamentos - Circular 2 de 2012 Excel [Internet]. Bogotá: MINSALUD; 2013 [citado 15 may 2015]. Disponible en: http://goo.gl/WSaQ4C.
21. Ministerio de Salud. Sistema de consulta de productos registrados [Internet]. Santiago: Instituto de Salud Pública de Chile; 2015 [citado 15 may 2015]. Disponible en: http://goo.gl/N0tVVJ.
22. Precios de Remedios [Internet]. Chile [citado 18 ago 2014] Disponible en: https://goo.gl/Z9Bt4A
23. Ministerio de Economía. Precios registrados de medicamentos con patente vigente [Internet]. México DF: Ministerio de Economía; 2014 [citado 15 may 2016]. Disponible en: http://goo.gl/aiuZnu.
24. Precios de Remedios [Internet]. México [citado 8 sep 2014]. Disponible en: https://goo.gl/rChQM1
25. Dirección General de Medicamentos, Insumos y Drogas. Catálogo de Productos Farmacéuticos [Internet]. Lima: Ministerio de Salud; 2015 [citado 15 may 2015]. Disponible en: http://goo.gl/PIIS7W.
26. Dirección General de Medicamentos, Insumos y Drogas. Módulo de Consulta de Precios [Internet]. Lima: Ministerio de Salud; 2015 [citado 15 may 2015]. Disponible en: http://goo.gl/Z4FCts.
27. Panamerican Health Organization. Health systems and social protection in health. In: PAHO. Health in the Americas. Washington DC: PAHO; 2012. p. 205-251.
28. The World Bank. GDP per capita (current US$) [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/MHMhCa
29. Organisation for Economic Co-operation and Development. OECD Better Life Index [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/GRl9QS
30. Organisation for Economic Co-operation and Development. OECD Better Life Index: Income [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/bVaDzi
31. Central Intelligence Agency. The world factbook [Internet]. 2015 [citado 10 may 2015]. Disponible en: http://goo.gl/lYZWO2
32. The World Bank. GINI index (World Bank estimate) [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/uAt4tj
33. The World Bank. PovcalNet: an online analysis tool for global poverty monitoring [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/XTNVMH
34. Niëns LM, Brouwer WBF. Measuring the affordability of medicines: importance and challenges. Health Policy. 2013;112:45-52.
35. Niëns LM, Van de Poel E, Ewen M, Laing R, Brour WBF. Practical measurements of affordability: an application to medicines. Bulletin of the World Health Organization. 2012;90:219-227.
36. O'Donnell O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing health equity using household survey data: a guide to techniques and their implementation [Internet]. Washington DC: World Bank; 2008 [citado 15 may 2015]. Disponible en: http://goo.gl/SSyar2.
37. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics -the pursuit of marginal indications and a me-to mentality that stifles innovation and creativity. JAMA Otolaryngology-Head & Neck Surgery. 2014;140(12):1225-1236.
38. The World Bank. GDP per capita, PPP (constant 2011 international $) [Internet]. c2016 [citado 10 may 2015]. Disponible en: http://goo.gl/AenKjw
39. Prescrire. Aclinidium: encore an atropinique inhale, peut être des effets cardivasculaires. Revue Prescrire. 2013;33(259):654-655.
40. Prescrire. Aflibercept: Dégénérescence maculaire liée al'âge: un autre anti-VEGF, sans plus. Revue Prescrire. 2013;33(353):170-173.
41. Prescrire. Apixaban et fibrillation auriculaire: Pas de preuves solides d'un progrès. Revue Prescrire. 2013;33(361):808-812.
42. Public Citizen. Emerging risks with new stroke prevention drugs. Worst Pills, Best Pills. Newsletter Articles; April 2013.
43. Prescrire. Axitinib: No better than sorafenib in kidney cancer. Revue Prescrire. 2013;22(143): 262-263.
44. Public Citizen. Harming Tuberculosis Patients Instead of Helping Them? WorstPills, Best Pills. Newsletter Articles; February 2013.
45. Prescrire. Bélatacept: Greffes de rein, plus de risque qu'avec la ciclosporine. Revue Prescrire. 2012;32(341):179-182.
46. Prescrire. Bélimumab: Des risques d'immuno-dépression, sans efficacité tangible établie. Revue Prescrire. 2013;33(354):258-261.
47. Prescrire. Bosutinib: Leucémie myéloïde chronique en situation d'échec: toxicité importante. Revue Prescrire. 2014;34(363):10.
48. Prescrire. Crizotinib: Effets indésirables graves avérés mais efficacité mal cernée dans les cancers bronchiques. Revue Prescrire. 2013;33 (357):498-501.
49. Prescrire. Stribild: deux nouvelles substances mais pas de progress. Revue Prescrire. 2013;33(256):408-411.
50. Prescrire. Enzalutamide: une alternative à l'abiratérone, après échec du docétaxel. Revue Prescrire. 2014;34(367):330-334.
51. Public Citizen. Letter to FDA on Indacaterol Maleate (ArcaptaNeohaler) [Internet]. 16 mar 2011 [citado 15 may 2015]. Disponible en: http://goo.gl/Taobep
52. Prescrire. Ipilimumab: Immunostimulant à mieux évaluer dans le mélanome. Revue Prescrire. 2012;32(340):98-100.
53. Prescrire. Linagliptine: Non aux gliptines. Revue Prescrire. 2012;32(347):564-565.
54. Public Citizen. Diabetes drugs link to pancreas disease. Worst Pills, Best Pills. Newletter Articles, August 2013.
55. Prescrire. Pasiréotide: Faute de mieux. Revue Prescrire. 2013;33(356):415-416.
56. Prescrire. Pérampanel - Fycompa(r). Nième anticonvulsivant dans les épilepsies partielles, sans progrès. Revue Prescrire. 2014;34(365):171-172.
57. Prescrire. Pertuzumab: Un espoir à mieux évaluer pour certaines patientes atteintes de cancer du sein métastasé. Revue Prescrire. 2013;33(361):816-814.
58. Prescrire. Régorafénib: Cancer colorectal métastasé en échec: peut-être quelques semaines de survie en plus. Revue Prescrire. 2013,33(360):736-741.
59. Prescrire. Rilpivirine: En première ligne contre le HIV: l'éfavirenz est mieux connu. Revue Prescrire. 2012;32(345):494-497.
60. Prescrire. Anticoagulation après prothèse de hanche ou de genou: rivoraxaban pas mieux qu'énoxaparine. Revue Prescrire. 2009;29(314):926-927.
61. Prescrire. Roflumilast: Efficacité douteuse sur la BPCO, mais risques avérés. Revue Prescrire. 2012;32(343)328-333.
62. Prescrire. Telaprevir: Afterboceprevir, if necessary. Revue Prescrire. 2012;32(339):11-14.
63. Prescrire. Teriflunomide (Aubagio(r)): Sclérose en plaques: Seulement un métabolite du léflunomide. Revue Prescrire. 2014;34(373):808-812.
64. Prescrire. Le tériflunomide (Aubagio(r)) est commercialisé ou annoncé dans divers pays [Internet]. Prescrire; 2014 [citado 15 may 2015]. Disponible en: http://goo.gl/6JkDnp
65. Prescrire. Ticagrelor: syndromes coronariens aigus: pas d'emballement. Revue Prescrire. 2011;31(333):488-493.
66. Prescrire. Vandétanib: Trop dangereux dans les cancers médullaires de la thyroïde. Revue Prescrire. 2012;32(342):256-259.
67. Prescrire. Aflibercept - Zaltrap(r): Cancer colorectal métastasé: au moins aussi mal toléré que le bévacizumab. Revue Prescrire. 2014;34(366):258.
68. Ugalde A, Homedes N. The regulatory framework and case studies from Argentina. In: Homedes N, Ugalde A, (eds). Clinical trials in Latin America: Where ethics and business clash. Dordrecht: Springer 2014. p. 79-114.
69. Naci H, Alexander W Carter AW, Mossialos E. Why drug development pipeline is not delivering better medicines. BMJ. 2015;351:h5542.
70. Goldacre B. Bad Pharma: How drug companies mislead doctors and harm patients. London: Fourth State; 2012.
71. Banzi R, Gerardi C, Bertele V, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. European Journal of Internal Medicine. 2015;26(8):572-584.
72. Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki PT, Nasser M, Xerri B. Comparative effectiveness research and evidence health policy: Experience from four countries. Milbank Quarterly. 2009;87(2):339-367.
73. Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions. Health Policy. 2012;108(2):167-177.
74. Prescrire. Évaluer le progrès thérapeutique: avec méthode, au service des patients. Revue Prescrire. 2015;35(382):565-569.
75. Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ. 2009;338:b1025.
76. Garattini S, Bertele V. Adjusting Europe's drug regulation to public health needs. Lancet. 2001;358(9275):64-67.
77. Light D, Lexchin J. The FDA's new clothes. BMJ. 2015;352:h4897.
78. Kim C, Prasad V. Strength of Validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs. Mayo Clinic Proceedings. 2016;91(6):713-725.
79. Conselho Nacional de Saúde. Resolução Nº 466, de 12 de dezembro de 2012 [Internet]. 2012 [citado 10 may 2015]. Disponible en: http://goo.gl/z0qZEl
80. Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121(22):4439-4442.
81. Ward A, Neville S. Drug cost watchdog chief calls for honesty with public. Financial Times [Internet]. 22 ago 2014 [citado 10 may 2015]. Disponible en: http://goo.gl/jOklBr
82. Werth B. A tale of two drugs. MIT Technology Review [Internet]. 22 oct 2013 [citado 10 may 2015]. Disponible en: http://tinyurl.com/lnhmkfe
83. Steenhuysen J. FDA cancer chief says 'escalating' drug prices can't continue. Reuters [Internet]. Health News; 1 jun 2014 [citado 15 may 2015]. Disponible en: http://tinyurl.com/hafwbd9
84. Evaluate Pharma. Budget-busters: the shift to high-priced innovator drugs in the USA [Internet]. September 2014 [citado 15 may 2015]. Disponible en: http://tinyurl.com/mdgvv27
85. Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties. 2011;6(1):34-50.
86. Yadav P. Differential pricing for pharmaceuticals [Internet]. WHO; 2010 [citado 15 may 2015]. Disponible en: http://tinyurl.com/h3hfpuw
87. Sant'Ana JMB, Pepe VLE, Osório-de-Castro CGS, Ventura M. Essential drugs and pharmaceutical care: reflection on the access to drugs through lawsuits in Brazil. Pan American Journal of Public Health. 2011;29(2):138-144.
88. Vieira FS, Lopes LC, Barberato-Filho S, Marques DC, Pepe VLE. Pharmaceutical services and judicial decisions: proposals to improve access and rational use of medicines. Revista de Administração em Saúde. 2010;12(47):79-86.
89. Chieffi AL, Barata RCB. Legal suits: pharmaceutical industry strategies to introduce new drugs in the Brazilian public health care system. Revista de Saude Pública. 2010;44(3):421-429.
90. Pepe VLE, de-Aragao-Figueiredo T, Simas L, Osorio-de-Castro CGS, Ventura M. Health litigation and new challenges in the management of pharmaceutical services. Ciência & Saúde Colectiva. 2010;15(5):2405-2414.
91. Biehl J, Amon JJ, Socal MP, Petryna A. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil. Health and Human Rights. 2012;14(1):36-52.
92. Andrade EIG, Machado CD, Faleiros DR, Szuster DAC, Guerra-Jr AA, Silva GD, et al. The judicialization of healthcare and the pharmaceutical care national policy in Brazil: the clinic management and the medicalization of the justice. Revista Médica de Minas Gerais. 2008;18(Suppl 4):S46-S50.
93. Cubillos L, Escobar ML, Pavlovic S, Iunes R. Universal health coverage and litigation in Latin America. Journal of Health Organisation and Management. 2012;26(3):390-406.
94. Reveiz L, Chapman E, Torres R, Fitzgerald JF, Mendoza A, Bolis M, Salgado O. Right to health litigation in three Latin American countries: a systematic literature review. Revista Panamericana de Salud Pública. 2013;33(3):213-222.
95. Diniz D, Medeiros M, Schwartz IVD. Consequences of the judicialization of health policies: the cost of medicines and mucopolysaccharidosis. Cadernos de Saúde Pública. 2012;28(3):479-489.
96. Tanaka OY. Juridical process of drug prescription in the Brazilian public health system or the challenge to ensuring the constitutional right to drugs access. Revista de Direito Sanitário. 2008;9(1):139-143.
97. Norheim OF, Wilson BM. Health rights litigation and access to medicines: priority classification of successful cases from Costa Rica's Constitutional Chamber of the Supreme Court. Health and Human Rights. 2014;16(2):47-61.
98. Hogerzeil HV, Samson M, Vidal Casanovas J, Rahmani-Ocora. Is access to essential medicines as part of the fulfillment of the right to health enforceable through the courts? Lancet. 2006;368(9532):305-311.
99. Yamin AE, Parra-Vera O. Judicial protection of the right to health in Colombia: from social demands to individual claims to public debates. Hastings International and Comparative Law Review. 2010;33(2):101-129.
100. Bergallo P. Courts and social change: lessons from the struggle to universalize access to HIV/AIDS treatment in Argentina. Texas Law Review. 2011;89(7):1611-1614.
101. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht A. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 2010;9:203-2014.
102. Wokasch M. What really drives drug development inefficiencies-Part 1. Multi Briefs: Exclusive [Internet]. 5 may 2014 [citado 15 may 2015]. Disponible en: http://tinyurl.com/hvy5mn8
103. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Humans. JAMA 2013;310(20):2191-2194.
104. Okpechi IG, Swanepoel CR, Venter F. Access to medications and conducting clinical trials in LMICs. Nature Reviews Nephrology. 2015;11(3):189-194.
105. Pourrieux C. Ética de la investigación frente a intereses empresariales en la industria farmacéutica: Un caso en Argentina. Revista Redbioética UNESCO. 2014;5(10):94-99.
106. Verástegui EL. Consenting of the vulnerable: the informed consent procedure in advanced cancer patients in Mexico. BMC Medical Ethics. 2006;7:13.
107. ABIA, Alianza LAC, AIDAN, CIMUM, et at. Es el momento de actuar: aseguren el acceso a productos bio-terapéuticos asequibles. Declaración de la Sociedad Civil para pre-ICDRA e ICDRA. Boletín Fármacos. 2014;117(4):81-82.
108. Colombia. Carta abierta al Señor Presidente de la República de Colombia Doctor Juan Manuel Santos Calderón, 5 de septiembre de 2014. Boletín Fármacos. 2014;117(4):91-92.
109. UNESCO. Universal Declaration on Bioethics and Human Rights [Internet]. 19 oct 2005 [citado 15 may 2015]. Disponible en: http://tinyurl.com/39a6c9n
110. International Alliance of Patients' Organizations, International Council of Nurses, IFPMA, International Pharmaceutical Federation, World Medical Association. Consensus framework for ethical collaboration between patients' organisations, healthcare professionals and the pharmaceutical industry [Internet]. 2014 [citado 15 may 2015]. Disponible en: http://tinyurl.com/htsq5nb
ISSN 1669-2381 (versión impresa) | ISSN 1851-8265 (versión electrónica) | 2250-5334 (english edition)
Editora Responsable: Viviana Martinovich
Propietario: Universidad Nacional de Lanús
Rector: Daniel Rodriguez Bozzani
29 de Septiembre 3901, Remedios de Escalada, Lanús (B1826GLC), Provincia de Buenos Aires, Argentina